U.S.Stem Cell, Inc. is a biotechnology company, which engages in the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The company is headquartered in Sunrise, Florida. The company went IPO on 2008-02-19. Stem Cell, Inc. is a biotechnology company. The firm is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The firm's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. The company is also investigating the use of adipose cells in a variety of clinical applications.

Industry: Services-Commercial Physical & Biological Research Peers: Adhera Therapeutics, Inc. Ayala Pharmaceuticals, Inc. RenovaCare, Inc. Burzynski Research Institute Inc POLARITYTE, INC. Tenax Therapeutics Inc